Evaluate Acquires J+D Forecasting
Both companies are now under the Norstella umbrella.
Evaluate announced the acquisition of J+D Forecasting, a provider of forecasting solutions focused on the pharmaceutical and life sciences industry.
The move will bring J+D under the Norstella umbrella, the parent company of Evaluate. The parent company also includes Citeline, MMIT, Panalgo, and The Dedham Group. Norstella works to bring therapies to patients and provide insights to pharmaceutical companies during the drug development life cycle.
As part of Norstella, Evaluate provides companies in the life sciences industry with data, insights, and intelligence related to high-value investments for treatments.
In a press release sent to Pharmaceutical Executive, Norstella CEO Mike Gallup said, “We are delighted to welcome the J+D Forecasting team to the Norstella family. Their expertise in developing bespoke forecasting models and innovative, intuitive solutions will provide our customers with an even wider breadth of expertise and cutting-edge insight. The addition of these capabilities significantly boosts our ability to help achieve our mission of smoothing the path of life-saving therapies from pipeline to patient.”
According to the press release, Norstella plans to implement J+D’s forecasting models to improve its forecasting portfolio. The company also plans on using generative AI programs to analyze the data and create comprehensive solutions.
In the same press release, J+D CEO and founder David James said, “The need for high quality forecasting to support decision making in the pharmaceutical and biotech space has never been higher. Bringing together two of the most respected forecasting providers in the industry provides huge opportunities for our customers and I am looking forward to working with the Evaluate team and Norstella to bring innovative solutions to the market.”
In the press release, Evaluate states that this acquisition will provide them with the ability to provide better forecasts related to market size, growth in key indications, and demand for new technologies.
Source
(Jan. 10, 2024); Norstella; Evaluate Announces Acquisition of J+D Forecasting; press release
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
